Ipilimumab in the treatment of prostate cancer

Future Oncology

Volumn 11, Issue 1, 2015, Pages 27-37

  Reese, Zachary ^a   Straubhar, Ali ^a   Pal, Sumanta K ^b   Agarwal, Neeraj ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

CTLA 4; immunotherapy; ipilimumab; prostate cancer

Indexed keywords

DOCETAXEL; IPILIMUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; SIPULEUCEL T; TAXOID; TISSUE EXTRACT; TUMOR ANTIGEN;

ADRENAL INSUFFICIENCY; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE PAIN; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COLITIS; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HEPATITIS; HUMAN; HYPONATREMIA; HYPOPHYSITIS; INJECTION SITE PAIN; LEUKOPENIA; LIMB PAIN; MALE; NEUTROPENIA; OVERALL SURVIVAL; PALLOR; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RASH; SEPSIS; VOMITING; IMMUNOLOGY; IMMUNOTHERAPY; PROSTATIC NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CTLA-4 ANTIGEN; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; TAXOIDS; TISSUE EXTRACTS;

EID: 84921033368     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.196     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11-30 (2013).
2. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321(7), 419-424 (1989).
3. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004).
4. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513-1520 (2004).
5. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
6. Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for cancer vaccine development. J. Biomed. Biotechnol. 2010, 596432 (2010).
7. Sonpavde G, Slawin KM, Spencer DM, Levitt JM. Emerging vaccine therapy approaches for prostate cancer. Rev. Urol. 12(1), 25-34 (2010).
8. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(7), 1099-1105 (2010).
9. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10(8), 580-593 (2010).
10. Tagawa ST, Beltran H, Vallabhajosula S et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 116(4 Suppl.), 1075-1083 (2010).
11. Morris MJ, Divgi CR, Pandit-Taskar N et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin. Cancer Res. 11(20), 7454-7461 (2005).
12. Galsky MD, Eisenberger M, Moore-Cooper S et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J. Clin. Oncol. 26(13), 2147-2154 (2008).
13. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. 22(13), 2522-2531 (2004).
14. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol. 23(21), 4591-4601 (2005).
15. Tagawa ST, Milowsky MI, Morris M et al. Phase II trial of 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC). J. Clin. Oncol. 26(15 Suppl.), 5140 (2008).
16. Tagawa ST, Vallabhajosula S, Osborne J et al. Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). J. Clin. Oncol. 28(15 Suppl.), 4667 (2010).
17. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol. 26(32), 5275-5283 (2008).
18. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu. Rev. Immunol. 27, 591-619 (2009).
19. Kwek SS, Dao V, Roy R et al. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J. Immunol. 189(7), 3759-3766 (2012).
20. Oosterwegel MA, Greenwald RJ, Mandelbrot DA, Lorsbach RB, Sharpe AH. CTLA-4 and T cell activation. Curr. Opin. Immunol. 11(3), 294-300 (1999).
21. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 13(6), 1810-1815 (2007).
22. Cooperberg MR. The contemporary management of prostate cancer in the United States: lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CAPSURE), a national disease registry. J. Urol. 171, 1393-1401 (2004).
23. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182(2), 459-465 (1995).
24. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5), 541-547 (1995).
25. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270(5238), 985-988 (1995).
26. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256), 1734-1736 (1996).
27. Yang YF, Zou JP, Mu J et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 57(18), 4036-4041 (1997).
28. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl Acad. Sci. USA 95(17), 10067-10071 (1998).
29. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 13, 5 (2013).
30. Kwon ED, Hurwitz AA, Foster BA et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl Acad. Sci. USA 94(15), 8099-8103 (1997).
31. Hurwitz AA, Foster BA, Kwon ED et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60(9), 2444-2448 (2000).
32. Madan RA, Mohebtash M, Arlen PM et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a Phase 1 dose-escalation trial. Lancet Oncol. 13(5), 501-508 (2012).
33. van den Eertwegh AJ, Versluis J, van den Berg HP et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a Phase 1 dose-escalation trial. Lancet Oncol. 13(5), 509-517 (2012).
34. Slovin SF, Higano CS, Hamid O et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter Phase I/II study. Ann. Oncol. 24(7), 1813-1821 (2013).
35. Chakraborty M, Abrams SI, Camphausen K et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J. Immunol. 170(12), 6338-6347 (2003).
36. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 64(12), 4328-4337 (2004).
37. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13(9), 1050-1059 (2007).
38. Kwon ED, Drake CG, Scher HI et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, Phase 3 trial. Lancet Oncol. 15(7), 700-712 (2014).
39. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30(21), 2691-2697 (2012).
40. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
41. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 81(6), 1297-1302 (2013).